ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB

0.09
EUR
0.00
(0.00%)
-0.08EPS
3.49MMarket Cap
Feb 25Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 12, 2026

Operator

Welcome to today's presentation where we have the pleasure to present ExpreS2ion Biotechnologies. To help us through today's presentation, we are joined by CEO Bent Frandsen and CFO Keith Alexander.

The topic for today: the Q3 results, but of course also news from the pipeline during the quarter we will go through in this event. As always, there's a box down below.

Do feel free to ask questions. The Q&A will be done in the end.

You feel free to do it in Danish, I will try and translate to the best of my ability. We have a fixed schedule to do half an hour and we will keep that fixed deadline, but on the last slide there will be an email address where you can send in the questions if we should not catch them.

With that, I will hand the stage over to you, Bent.

Bent Frandsen

Thank you very much, Michael, and welcome everybody to ExpreS2ion's Q3 2026 results webcast. I'm Bent Frandsen, the CEO of the company, and I'm joined today by our CFO, Keith Alexander.

I will begin with our operational and clinical progress, including our platform partnerships and the latest on ES2B-C001, our HER2-targeted breast cancer immunotherapy, and then Keith will take us through the third-quarter and nine-month financial results before we open for questions. Before we begin, please note the disclaimer on this slide.

Today's presentation includes forward-looking statements, particularly on clinical development, partnering, and funding. These reflect our current expectations and are subject to risks and uncertainties, actual outcomes and timing may differ.

Let me start with three reasons why this is an important period for ExpreS2ion. First, we have observed anti-HER2 antibody responses in 12 out of 13 evaluable patients in our Phase 1 trial.

These are preliminary findings, but they support the biological rationale for ES2B-C001. Second, in the market, there's still a substantial need for more durable disease control.

Even with the strong results reported for newer first-line HER2 combination, around three in 10 patients had progressed or passed away within two years. Third, our Phase 1 primary readout is expected in the first quarter 2027.

That dataset, together with the translational work, will be central to our partnering discussions and the next development decisions. Our pipeline has a clear focus: one proprietary oncology lead asset, supported by a broader group of partnered infectious disease programs.

We sponsor ES2B-C001 ourselves. Our malaria, Nipah virus, and influenza activities are advanced through licenses, academic collaborations, and grant funding, with different levels of funding coverage.

This structure allows us to focus our own investment on oncology, while continuing to demonstrate the capabilities of the ExpreS2 platform across other applications. The pipeline chart also shows a historical COVID-19 program, which reached Phase 3 before Bavarian Nordic discontinued it for commercial reasons.

I'll now move more in-depth into our platform. ExpreS2 is the protein expression platform behind our programs.

Since 2010, it has been used to express more than 500 proteins and virus-like particles with a success rate above 90%. Its clinical track record includes the COVID-19 program, whose Phase 3 study enrolled more than 4,200 participants and met its primary endpoint, demonstrating non-inferiority against a commercial mRNA vaccine.

In malaria, published work demonstrated production of more than 400 milligrams of RH5.1 antigen from a single 25-liter GMP batch, which demonstrates solid experience in this field. For ExpreS2ion, this platform supports several sources of income and funding: technology licenses, contract research, and grant-funded programs.

The Serum Institute of India malaria agreement from November 2025 is an important example. Glycoengineering patent applications published this year also extend our intellectual property estate.

In malaria, our platform produces four antigens in the University of Oxford's development programs. RH5.1 and R78C are particularly relevant commercially because they are licensed to the Serum Institute of India.

During the quarter, a Phase 2b trial of RH5.1 concluded, as did a Phase 1b/2 trial combining RH5.1 and R78C. Two new trials involving combinations with the WHO-recommended R21 vaccine are being prepared, and further Phase 2b completion is expected in the fourth quarter.

Several important datasets are expected in the first quarter 2027, including longer-term RH5.1 follow-up and combination data. The University of Oxford determines the timing, which may change.

The need remains very large. Still more than 600,000 died from malaria in 2024, and mostly among young children in Africa.

For us, the Serum Institute of India license offers potential milestones and royalties as development and commercialization progress, as we announced in November 2025. The other Oxford programs provide additional clinical experience with our platform.

Nipah is another important application of our platform. Recurring outbreaks, high fatality rates, and the absence of an approved vaccine underline the need for a preventive option.

During Q3, work continued to finalize the GMP-ready antigen process, and GMP manufacturing is underway at Northway Biotech. The next steps are the toxicology study, the clinical trial application, and a Phase 1/2a trial run by the consortium.

The program is grant-funded through Phase 1 and combines ExpreS2-produced antigen with virus-like particle technology, the same overall approach used for ES2B-C001 cancer immunotherapy and the COVID-19 vaccine. Because that antigen is made with ExpreS2, we expect our technology to form part of any future licensing agreement, although no such outcome is assured.

MukaVaax, meanwhile, is approximately 67% grant-funded. Its work on cell lines, larger-scale antigen production, and VLP purification also contributes to the platform's capabilities.

Let me turn to ES2B-C001, our lead asset, and explain why we believe active immunotherapy could contribute to the treatment of HER2-expressing cancers. Treatment for HER2-positive metastatic breast cancer has advanced considerably.

Antibody-drug conjugates, or ADCs, have raised the standards that new approaches must meet. In DESTINY-Breast09, trastuzumab deruxtecan, also known as Enhertu, combined with pertuzumab, delivered a median progression-free survival of around 41 months.

Nevertheless, around 30% of patients had progressed or passed away by two years. That remaining gap is relevant to our development strategy.

ES2B-C001 is designed to add an active, broad anti-HER2 immune response to standard treatment, with the aim of extending disease control. We see it as a potential complement to existing therapies, including ADCs.

The historical comparisons on this slide illustrate progress in the field; they are not head-to-head comparisons across trials. The intended benefit of adding ES2B-C001, of course, still needs to be tested clinically.

Our current study is establishing safety and immune responses. ES2B-C001 combines the full extracellular part of HER2, produced using ExpreS2, with high-density display on a virus-like particle.

That extracellular region contains four domains. Individual HER2-directed monoclonal antibodies bind to specific sites.

By presenting all four domains, ES2B-C001 is designed to stimulate a broader family of antibodies against HER2. The VLP provides a repetitive display intended to help the immune system generate a strong and lasting response.

There is established experience with durable antibody responses to VLP-based infectious disease [unclear], for example, with HPV vaccines. That experience supports the rationale for our design.

Our own Phase 1 follow-up and planned maintenance boosters are intended to address these questions alongside translational analyses of antibody quality and function. Turning to the clinical data, this is an open-label Phase 1 dose-escalation study in patients with advanced HER2-positive or HER2-low breast cancer after standard treatment.

It evaluates five intramuscular doses across three cohorts: 50, 150, and 450 micrograms. The main objectives are safety, tolerability, and immunogenicity.

19 patients have been dosed. In the preliminary evaluable dataset, 12 of 13 patients showed at least a twofold increase in anti-HER2 antibody titers.

Looking at the graph, titers rise over dosing series and then decline gradually after the fifth dose. Individual patterns vary, and the graph uses a data cut-off of 5th October.

Follow-up and planned boosters will help us understand how these responses can be maintained. On safety, no dose-limiting toxicities and no treatment-related serious adverse events have been reported in the data presented here.

The Independent Safety Monitoring Board has cleared continuation. These are encouraging early observations, but the study is small and findings remain preliminary.

This translational work will examine immune quality, durability, and mode of action. Together with the primary readout expected in Q1 2027, this should provide a more complete basis for deciding how to take ES2B-C001 forward.

Our immediate priorities are to complete Phase 1 dosing in the fourth quarter, obtain translational results around the end of the year, and deliver the primary Phase 1 readout in the first quarter of 2027. For Phase 2, the proposed focus is first-line HER2-positive metastatic breast cancer, informed by our Scientific Advisory Board discussions.

This would give us a more homogeneous population with better preserved immune function than in a heavily pretreated setting. We're planning a focused study of 80 to 120 patients.

The intention is to use one standard-of-care backbone across all arms so we can assess the contribution of ES2B-C001 within a standard-of-care setting. The proposed main readout is progression-free survival at 24 months.

Tumor-informed circulating tumor DNA, or ctDNA, is planned as a key secondary endpoint, providing another way to follow disease activity alongside clinical assessments. The design remains subject to protocol finalization, statistical validation, and regulatory interaction.

The dose arms are not yet fixed. A 24-month endpoint also requires sufficient patient follow-up.

The eventual readout date will depend on recruitment and the final study design. Our preferred partnering model is for partner to fund Phase 2 and collaborate on development, with an option to license after interim data.

This is the model we're pursuing. With a partner, we're targeting a Phase 2 start in the second half of 2027, subject to funding and other development requirements.

That concludes my operational and clinical update. I will now hand over to Keith to take us through the Q3 and nine-months 2026 financial results.

Keith, over to you.

Keith Alexander

Thank you, Bent. I'll now take you through the financial results for Q3 and the first nine months of 2026.

As Bent described, we made significant clinical progress in the quarter. I'll show you what that looked like in the numbers.

Starting with the headline figures, operating income was 2.3 million Swedish crowns, essentially flat year-on-year. Operating loss increased 31% year-on-year to 12.8 million, and the net loss for the period was 9.9 million, up 18% from Q3 2025.

On cash, we closed the quarter at 24 million, before 19.3 million in proceeds from the TO 13 warrant exercise and the directed issue to the guarantor, most of which was received after the period. The R&D spend figure, 3.7 million, was up 56% year-on-year.

I'll go into more detail on these figures in the coming slides. Let's look at income in a bit more detail.

The left chart shows total operating income per quarter since 1Q 2024. 3Q 2026 was much lower than recent quarters at 2.3 million, but essentially flat versus Q3 2025.

That decrease is from the grants line. CRO net sales were 1.4 million, up 0.4 million in Q3 2025, reflecting more customer project activity.

The percentage looks large because Q3 last year was the weakest quarter on this chart. The better measure is year-to-date: net sales are up 37% to 4.4 million.

Other operating income, which is mainly grant income, was 0.9 million, down 52% year-on-year. We recognize grant income as the funded work is done, it follows the timing of project activity rather than coming in evenly.

The bigger fall is against Q2. As the call-out shows, Q2 included grant income for the Vici disease manufacturing work we subcontracted, with matching costs in R&D.

That campaign is now largely complete, so as I said last quarter, both the grant income and the matching R&D costs will be much lower from here. Turning to costs, total operating expenses were 15.1 million, up 25% year-on-year.

The left chart shows the quarterly progression, including a significant decrease in sequential operating expense. R&D costs were 3.7 million, up 56% year-on-year.

That was mainly ES2B-C001 clinical trial costs, alongside higher CMC costs. Against Q2, they were much lower because Q2 carried most of the Vici disease manufacturing costs.

Personnel costs were 7.4 million, up 25% year-on-year. That reflects higher personnel-related expenses and a soft comparison because Q3 2025 benefited from parental and sick-leave reimbursements.

Other external costs were 3 million, up 18%, mainly from higher legal and professional fees, partly offset by lower costs elsewhere. This quarter, we'd like to show you an estimate of our year-to-date operational expenses split on the main activities and how they compare with the same period for 2025.

These buckets are ES2B-C001, infectious diseases, which are other pipeline activities in malaria, influenza, and Nipah virus, CRO platform activities, and other costs, which are primarily administrative and due to being a public listed company. It's a rough management estimate based on direct costs and the time that our team registers against each program and allocation rules for non-program-specific activities, such as rental facilities.

For that reason, it is important to stress that the allocated structure pictured here is our estimate. Operating costs for the first nine months rose from 42.8 million in 2025 to 57.4 million in 2026.

Most of that increase was offset by higher grant income, our net operating costs rose by only around 2.6 million. The big change is infectious diseases, which has taken a much larger share of our costs this year.

That's mainly the Nipah program moving towards cGMP manufacturing in the Vici disease consortium. Grants covered about 70% of infectious-disease-related costs, up from around 60% in 2025.

With the manufacturing campaign now largely complete, both the costs and the matching grant income will be lower from here. Finally, ES2B-C001's share is slightly lower only because infectious diseases grew.

In absolute terms, spending on it rose, driven by clinical costs. The net loss for the period was 9.9 million, compared to 8.4 million in Q3 2025, an 18% increase.

The bottom-left chart breaks down the drivers: the operating result deteriorated by 3 million, net financial items were a small benefit of 319,000, and the R&D tax credit accrual increased by 1.2 million, reflecting the higher qualifying R&D spend in the period. Those three factors together account for the 1.5 million SEK increase in the net loss, it's primarily driven by the operating result.

Looking at the year-to-date loss on the right side, loss decreased 2% in 2026 compared with the year-to-date 2025 result. The bottom-right chart breaks down the drivers: operating result was slightly worse, while net financial items and the R&D tax credit were better year-to-date than the first nine months of 2025.

This drove a total improvement of approximately 700,000 SEK. The waterfall chart shown here shows cash development over the last year, from September 2025 through to September 2026.

We started at 36.9 million. Operating cash outflows through the year reflect continued investment in ES2B-C001 and grant-funded program activities.

We closed Q3 2026 at 24 million. The single largest driver in Q3 was the operating cash flow of -11.1 million, compared with -12.5 million in Q2 and -25.5 million in Q1.

The final quarter of 2025, and the last several years more broadly, has benefited from the annual payment of the R&D tax credit, which is usually November. Operating cash flow is still primarily driven by ES2B-C001 clinical development, while ExpreS2ion's role in Vici disease CMC is mostly behind us.

As I mentioned looking forward, Vici disease CMC costs and income are expected to be much lower. Pulling it together on the cash outlook, Q3 2026 closing cash was 24 million.

After the quarter, the TO 13 warrant exercise and the directed issue to the guarantor brought in 19.3 million SEK before issue costs. That came with a dilution of about 40%.

The net proceeds are intended primarily to take ES2B-C001 through the primary readout of its Phase 1 study. In September, we also signed a put option agreement with Alumni Capital for up to 50 million SEK over 24 months starting in 2027.

We can choose whether and when to use it, but we can only give notice to draw on it when the share price is at or above 4.00 SEK. The share price is well below that today, it isn't in our current forecast.

It's an option that could become useful under the right conditions, including a higher share price. Our priorities are to complete the Phase 1 priming phase for ES2B-C001 in December, deliver the translational studies before year-end, support the target of Q1 2027 primary readout, and advance related business development activities.

Timing remains subject to clinical, regulatory, operational, and funding factors, as set out in the presentation. That covers the financial section.

With that, I'll hand it back to Bent for some comments on expected milestones over the next 12 months, and stay online for the Q&A.

Bent Frandsen

Thank you, Keith. Before we take questions, let me close with the key milestones ahead.

Our main priority is the ES2B-C001 Phase 1 primary readout in the first quarter of 2027. Alongside safety and immune responses, we expect preliminary observations of antitumor activity assessed using RECIST criteria.

Together with our translational work, the readout will inform the Phase 2 design and support partnering discussions. We're working towards a focused study in first-line HER2-positive metastatic breast cancer, with the start targeted for second half of 2027, subject to securing a partner and funding.

Across our partner programs, Nipah is progressing towards toxicology and the work needed to support a clinical trial application, with potential Phase 1 initiation in the second quarter of 2027. In malaria, selected clinical readouts, including Phase 2b data, are expected in the first quarter.

Any additional licensing opportunities remain to be determined. These timelines remain subject to clinical progress, regulatory interactions, manufacturing, funding, and partner decisions.

Our focus is to turn the emerging clinical and translational evidence into a clear next development step for ES2B-C001, while our partnered programs continue to advance. Thank you for your attention and continued interest in ExpreS2ion.

Keith and I are happy to take any...

Operator

Perfect. Let's jump into some question to both.

Is there any milestones in Q1 from the Serum upon the presentation of the data? Here we're talking about the malaria.

I don't know whether you want to comment on that, but any potential milestones from that?

Bent Frandsen

From the malaria, sorry?

Operator

From the malaria, yes.

Bent Frandsen

Yes, as I mentioned, quite a number of clinical trials going on through the University of Oxford and several of them are progressing, and that we will have more data from Phase 2 studies that I just highlighted here earlier. Of course, with respect to the Serum Institute of India, the tech transfer for RH5.1 and R78C has taken place, meaning that they are starting to scale up manufacturing for later-stage clinical trials on those as well, progressing well.

Operator

Milestones, I don't know whether you want to comment on whether some money will flow to you on the data front by finishing these?

Bent Frandsen

There are certain milestones. I will refer to the press release that we did 1 year ago in November 2025, where we have detailed the financial implications.

Operator

Then to stay in this one, we talked about the Serum, but the WuXi also on the malaria front and so on, any updates on that negotiations you have with those?

Bent Frandsen

I didn't quite catch the question. I'm sorry, Michael.

Operator

Sorry, yes. Is there any progress report on WuXi the WuXi agreement you also did?

The Serum I think we have covered, but the WuXi I think you signed a letter of intent with those. Any updates, any progress?

Bent Frandsen

That is correct. We have a letter of intent stipulating a potential strategic collaboration with WuXi Biologics.

It depends on a potential partner applying our ExpreS2 platform in a setting with WuXi Biologics. Far, we have actually not been fortunate that WuXi Biologics has retained any client to apply our platform.

It's still ongoing, and we are very pleased that WuXi, they actually promote our system at various scientific and technological congresses, but that's where things stand today.

Operator

Check. The first maintenance dose was given in December.

Do you have any early indication of whether boosting lifts titers above their priming peak? A little bit into the data, I don't know whether you want to go into such a details before we have those, but whether boosting lift titers above their priming peak?

Bent Frandsen

It's a bit too early to say. We've just initiated the booster phase or the maintenance phase, it's too early to say based on a single or two single shots with patients so far.

Of course, we'll observe this very carefully during 2027 and bring it into our communication as soon as we can.

Operator

Then a little bit about the partner discussion. Stating here, is it effectively awaiting for the Q1 '27 readout, or are there any realistic path to agreement before that?

Your feel with the partner discussions, whether something could actually come before, or it is really awaiting those Q1 '27 readouts?

Bent Frandsen

The partner discussions are very dependent on the data that we generate, and as we've explained, we have a very compelling preclinical data package. Now it's our task to documenting what we found in preclinical settings also in clinical trial.

This clinical Phase 1 trial is primarily a safety and tolerability trial. We have some indications of antitumor activity, which we will announce also in Q1 2027, and that will certainly facilitate the partnering discussions we are in.

Operator

Perfect. Do the current cash holding take you through the Q1 '27 readout, including maintenance dosing?

Keith Alexander

Sure, I can take that one. As we stated, we closed the quarter with about 24 million Swedish crowns in cash, and after that, we got 19.3 million gross from the TO 13 and the directed issue.

Those proceeds, on that basis, are intended primarily to take ES2B-C001 through the Phase 1 primary readout in the first quarter. We don't give a specific runway date.

What I can say is that the board is continually evaluating our financing needs and our cost base, including financing options, partnership opportunities, and other non-dilutive funding sources.

Operator

Then a final question. Winning back investors' confidence, as stated here, you are below cash position, you actually have a solid pipeline, you are in the cancer field where it actually are showing promising result and must create some new attention actually around the world with all those results, and maybe taking a little bit back from the obesity where money wants to be put, although solid results, and you also have this stake in AdaptVac.

Clearly, that's where we are and everybody can state that, but winning back investor confidence, is that a game of commercializing, getting the partner in, and the data out? Maybe it was a leading question, but a little bit comments on that, Bent.

Bent Frandsen

I think commercializing is the keyword. We have a very, very strong scientific platform and foothold, which has been documented over and over again in malaria and COVID-19, and now also in oncology.

The real value trigger, I acknowledge that, that must be a partnering event that can trigger milestones or upfront payments and royalties down the road. We've seen evidence of this in Swedish public listed companies here in 2026.

I think there have been some interesting cases of scientifically well-based biotech companies that have been living a strained life because you need also a commercial outcome of all your scientific wonders. We're looking to do the same.

That's our aim for 2027.

Operator

Perfect. That was the last question.

I will let you off your hook, you both. Thank you for taking us through your results and answering questions in the end of everything.

May everybody have a nice day.

Bent Frandsen

Thank you.